MUMBAI, India, Sept. 7 -- Intellectual Property India has published a patent application (202617082959 A) filed by Ultragenyx Pharmaceutical Inc. on July 06, 2026, for Compositions And Methods For Treating Conditions Associated With Ube3a Overexpression.
Inventors include Swistowski, Andrzej; Dindot, Scott Victor; Couthouis, Julien; and Atwood, Heather Richbourg.
The application for the patent was published on September 04, 2026, under issue no. 36/2026.
Abstract: This application provides antisense nucleic acid compounds that reduce UBE3A mRNA levels and/or UBE3A polypeptide levels in central nervous system neurons, thereby alleviating effects and symptoms caused by excess UBE3A levels. The application further provides compositions comprising antisense nucleic acid compounds and their use in methods of preventing or treating conditions associated with excess UBE3A mRNA and/or UBE3A polypeptide levels in a subject.
Disclaimer: Curated by HT Syndication.
